Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Yesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent dise...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/anticancer-and-cardio-protective-effects-of-liposomal-doxorubicin-in-t-peer-reviewed-article-BCTT |
| _version_ | 1818852681683304448 |
|---|---|
| author | Franco YL Vaidya TR Ait-Oudhia S |
| author_facet | Franco YL Vaidya TR Ait-Oudhia S |
| author_sort | Franco YL |
| collection | DOAJ |
| description | Yesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius, is a potent chemotherapeutic drug that is successfully used to treat various forms of liquid and solid tumors and is currently approved to treat BC. DOX exerts its effects by intercalation into DNA and inhibition of topoisomerases I and II, causing damage to DNA and the formation of reactive oxygen species (ROS), resulting in the activation of caspases, which ultimately leads to apoptosis. Unfortunately, DOX also can cause cardiotoxicity, with patients only allowed a cumulative lifetime dose of 550 mg/m2. Efforts to decrease cardiotoxicity and to increase the blood circulation time of DOX led to the US Food and Drug Administration (FDA) approval of a PEGylated liposomal formulation (L-DOX), Doxil® (known internationally as Caelyx®). Both exhibit better cardiovascular safety profiles; however, they are not currently FDA approved for the treatment of metastatic BC. Here, we provide detailed insights into the mechanism of action of L-DOX and its most common side effects and highlight results of its use in clinical trials for the treatment of BC as single agent and in combination with other commonly used chemotherapeutics. Keywords: doxil, caelyx, breast cancer, anti-tumor activity, cardiotoxicity |
| first_indexed | 2024-12-19T07:24:47Z |
| format | Article |
| id | doaj.art-c2b365b508034eafa2fb3a030de4fa18 |
| institution | Directory Open Access Journal |
| issn | 1179-1314 |
| language | English |
| last_indexed | 2024-12-19T07:24:47Z |
| publishDate | 2018-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Breast Cancer: Targets and Therapy |
| spelling | doaj.art-c2b365b508034eafa2fb3a030de4fa182022-12-21T20:30:51ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142018-09-01Volume 1013114140491Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancerFranco YLVaidya TRAit-Oudhia SYesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius, is a potent chemotherapeutic drug that is successfully used to treat various forms of liquid and solid tumors and is currently approved to treat BC. DOX exerts its effects by intercalation into DNA and inhibition of topoisomerases I and II, causing damage to DNA and the formation of reactive oxygen species (ROS), resulting in the activation of caspases, which ultimately leads to apoptosis. Unfortunately, DOX also can cause cardiotoxicity, with patients only allowed a cumulative lifetime dose of 550 mg/m2. Efforts to decrease cardiotoxicity and to increase the blood circulation time of DOX led to the US Food and Drug Administration (FDA) approval of a PEGylated liposomal formulation (L-DOX), Doxil® (known internationally as Caelyx®). Both exhibit better cardiovascular safety profiles; however, they are not currently FDA approved for the treatment of metastatic BC. Here, we provide detailed insights into the mechanism of action of L-DOX and its most common side effects and highlight results of its use in clinical trials for the treatment of BC as single agent and in combination with other commonly used chemotherapeutics. Keywords: doxil, caelyx, breast cancer, anti-tumor activity, cardiotoxicityhttps://www.dovepress.com/anticancer-and-cardio-protective-effects-of-liposomal-doxorubicin-in-t-peer-reviewed-article-BCTTLiposomal doxorubicinBreast cancerAnti-tumor activityCardiotoxicity |
| spellingShingle | Franco YL Vaidya TR Ait-Oudhia S Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer Breast Cancer: Targets and Therapy Liposomal doxorubicin Breast cancer Anti-tumor activity Cardiotoxicity |
| title | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer |
| title_full | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer |
| title_fullStr | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer |
| title_full_unstemmed | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer |
| title_short | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer |
| title_sort | anticancer and cardio protective effects of liposomal doxorubicin in the treatment of breast cancer |
| topic | Liposomal doxorubicin Breast cancer Anti-tumor activity Cardiotoxicity |
| url | https://www.dovepress.com/anticancer-and-cardio-protective-effects-of-liposomal-doxorubicin-in-t-peer-reviewed-article-BCTT |
| work_keys_str_mv | AT francoyl anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer AT vaidyatr anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer AT aitoudhias anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer |